Petros Pharmaceuticals (PTPI) has implemented multiple enhancements to its developing AI platform, which is expected to improve processing and fraud detection and provide a better overall experience. The AI Platform is expected to be a key component of the Company’s recently announced SaaS-based technology, integrating Petros’ Software as a Medical Device proprietary solution, which is being designed to help facilitate expanding access for established prescription drugs by bringing them over the counter. The enhancements include: Addition of Deep Fake detection and mitigation features; Improved facial and ID recognition and matching capabilities; Enhanced image auto capture feature powered by machine learning technology.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTPI:
- AI Daily: Microsoft reports earnings, says Cloud, AI ‘essential inputs’
- Petros Pharmaceuticals developing SaaS Platform using AI, EHR
- Petros Pharmaceuticals trading halted, news pending
- Petros Pharmaceuticals to effect 1-for-25 reverse stock split
- Petros highlights Trump executive order on Rx-to-OTC reclassification reforms